RxDoctor Payments Data

Hans Peter Kiem

Hematology & Oncology · Seattle, WANPI 1740370600

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,010 of the $87,053 with a category attached, or 80.4%. CSL Behring accounts for 84.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $42,014 and has fallen 92.0% since, to $3,360 in 2024. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,053in general payments, 2019–2025

Across 28 payments — averaging $3109.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$73K
  • Gilead$14K
  • Vertex$29
$1,122,038in research payments, 2019–2025

Across 12 payments — averaging $93,503 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$901K
  • Gilead$221K

What the payments were for

  • Consulting fees$70,01080%
  • Speaking & faculty fees$13,28515%
  • Travel & lodging$3,2054%
  • Food & beverage$5521%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring24$73,264
Gilead3$13,760
Vertex1$29

How this compares

$87,053 in reported general payments places this provider in the 90th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →